Biora Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Biora Therapeutics generated cash of -$48,499,000, which is more than the previous year. Cash used in financing activities reached the amount of $30,781,000 last year. Net change in cash is therefore -$15,275,000.
Cash Flow
| 2018 | -65.12M | 55.83M | -12.80M |
|---|---|---|---|
| 2019 | -106.12M | 16.52M | 73.63M |
| 2020 | -165.74M | -4.94M | 229.72M |
| 2021 | -167.48M | -1.24M | 165.04M |
| 2022 | -64.41M | -792K | 7.29M |
| 2023 | -48.49M | 2.44M | 30.78M |
PROG Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 30.48M | 88.39M | 92.07M | 33.04M | 49.00M | 71.10M |
Operating activities | ||||||
Net income | -124.11M | -38.15M | -178.52M | -192.52M | -148.03M | -129.10M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 555K | 907K | 1.43M | 5.05M | 6.34M | 6.07M |
Stock-based compensation expense | 16.47M | 7.80M | 11.96M | 8.24M | 2.37M | 0 |
| Deferred income tax benefit | 16.47M | 7.80M | 11.96M | 8.24M | 2.37M | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | -828K | 0 | 9.50M | 3.42M | 584K |
Inventories | 0 | 828K | 0 | -1.42M | -3.85M | -3.47M |
Accounts payable | -1.17M | -5.07M | -8.68M | 2.85M | 4.38M | 5.77M |
Cash generated by operating activities | -48.49M | -64.41M | -167.48M | -165.74M | -106.12M | -65.12M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -11.21M | -167.01M |
Investments In Property Plant And Equipment | -103K | -792K | -855K | -4.94M | -3.72M | -4.83M |
Acquisitions Net | 0 | 0 | 0 | 0 | 50K | 0 |
Cash generated by investing activities | 2.44M | -792K | -1.24M | -4.94M | 16.52M | 55.83M |
Financing activities | ||||||
Common Stock Issued | 18.13M | 9.01M | 46.77M | 116.43M | 551K | 459K |
Payments for dividends | 0 | 0 | 0 | 0 | -4.5M | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | -11.26M |
Repayments of term debt | 10M | -12K | -1.64M | -983K | -1.27M | -1.75M |
Cash used in financing activities | 30.78M | 7.29M | 165.04M | 229.72M | 73.63M | -12.80M |
Net Change In Cash | -15.27M | -57.91M | -3.67M | 59.03M | -15.96M | -22.10M |
Cash at end of period | 15.21M | 30.48M | 88.39M | 92.07M | 33.04M | 49.00M |
| Data source | Data source | Data source | Data source |